Vertex Pharmaceutic (VRTX)

$528.19 +12.64 (2.45%)
Market Cap 130.85B
Revenue (ttm) 12.00B
Net Income (ttm) 3.95B
EPS (ttm) N/A
PE Ratio 29.72
Forward PE 30.00
Profit Margin 32.94%
Debt to Equity Ratio 0.00
Volume 1,497,000
Avg Vol 1,605,038
Day's Range N/A - N/A
Shares Out 253.81M
Stochastic %K 72%
Beta 0.30
Analysts Strong Sell
Price Target $560.65

Company Profile

Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for peo...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 341 6100
Address:
50 Northern Avenue, Boston, United States
NightBreeze
NightBreeze Aug. 19 at 1:00 PM
$VRTX Played possum now raging. I see you.
0 · Reply
Jblack500
Jblack500 Aug. 18 at 5:15 PM
$VRTX $ELAN $MRK $GILD $HALO ARWR BMY current basket...vrtx recent new position...added to ELAN today. Sell-off after er created opportunity. Multiple insiders made open market buys on 8/7 near this level.
0 · Reply
svertical1
svertical1 Aug. 18 at 5:14 PM
$VRTX Pain important but Pove is still the game changer. Still not too late for Vertex to modify strategy of Journavx pricing. Pain is not a rare disease.
0 · Reply
OffHisGame88
OffHisGame88 Aug. 18 at 4:07 PM
$VRTX defensives going to be key in the fall
1 · Reply
DonJulio
DonJulio Aug. 18 at 3:13 PM
$VRTX 🔥
0 · Reply
Merlintrader
Merlintrader Aug. 18 at 12:02 AM
Vertex Pharmaceuticals ($VRTX) Stock Hub 2026: The Cystic Fibrosis Fortress, The Pain Launch, And The $10B Crinetics Acquisition https://www.merlintrader.com/vertex-pharmaceuticals-stock-hub/
0 · Reply
Jblack500
Jblack500 Aug. 17 at 5:14 PM
$VRTX 600 dollar stock
0 · Reply
JFDI
JFDI Aug. 17 at 3:58 PM
$VRTX engulfer off the 10d
1 · Reply
Clairebear1
Clairebear1 Aug. 15 at 4:09 PM
$VRTX What’s the reason for Vertex delay in advancing Nav1.7 and next gen Nav1.8 sodium channel blockers to treat pain?. It’s been years in preclinical stage and competitors to Journavx are progressing in clinical trials. I hope Vertex success in serial innovation in CF can be replicated in pain. Otherwise perhaps they need to do another acquisition of someone who’s actually managed to achieve something superior to Journavx before it’s made obsolete like what happened to Vertex in hepatitis C with telaprevir after Gilead acquired Pharmasset in 2011.
1 · Reply
StUngarjr
StUngarjr Aug. 15 at 3:12 PM
$VRTX this stock spits a bit here every time hopefully not this time, but I got my finger on the trigger
0 · Reply
Latest News on VRTX
Vertex Pharmaceuticals added to ‘US 1 List’ at BofA

2026-08-11T09:50:55.000Z - 8 days ago

Vertex Pharmaceuticals added to ‘US 1 List’ at BofA

Vertex Pharmaceuticals price target raised to $672 from $605 at BofA

2026-08-10T16:06:33.000Z - 8 days ago

Vertex Pharmaceuticals price target raised to $672 from $605 at BofA

SION

Vertex Stock (VRTX) Soars 7% as Rival Sionna (SION) Crashes 92% on Failed Drug Trial

2026-08-10T15:55:12.000Z - 8 days ago

Vertex Stock (VRTX) Soars 7% as Rival Sionna (SION) Crashes 92% on Failed Drug Trial

SION

Healthcare Stocks Have Been Forgotten. Eli Lilly, McKesson, and 9 More to Buy.

Aug 5, 2026, 3:31 PM EDT - 13 days ago

Healthcare Stocks Have Been Forgotten. Eli Lilly, McKesson, and 9 More to Buy.

LLY MCK

Vertex Pharmaceuticals price target raised to $565 from $560 at Truist

2026-08-05T14:05:03.000Z - 14 days ago

Vertex Pharmaceuticals price target raised to $565 from $560 at Truist

Vertex Pharmaceuticals price target raised to $617 from $615 at Barclays

2026-08-05T09:25:32.000Z - 14 days ago

Vertex Pharmaceuticals price target raised to $617 from $615 at Barclays

Vertex Pharmaceuticals price target raised to $605 from $600 at BofA

2026-08-04T12:10:47.000Z - 15 days ago

Vertex Pharmaceuticals price target raised to $605 from $600 at BofA

Vertex Pharmaceuticals price target raised to $595 from $590 at Cantor Fitzgerald

2026-08-04T11:51:10.000Z - 15 days ago

Vertex Pharmaceuticals price target raised to $595 from $590 at Cantor Fitzgerald

Vertex Pharmaceuticals price target raised to $550 from $525 at TD Cowen

2026-08-04T11:50:38.000Z - 15 days ago

Vertex Pharmaceuticals price target raised to $550 from $525 at TD Cowen

Vertex Pharmaceuticals price target raised to $442 from $430 at Canaccord

2026-08-04T11:07:03.000Z - 15 days ago

Vertex Pharmaceuticals price target raised to $442 from $430 at Canaccord

Vertex Pharmaceuticals price target raised to $500 from $466 at Stifel

2026-08-04T11:01:01.000Z - 15 days ago

Vertex Pharmaceuticals price target raised to $500 from $466 at Stifel

Vertex Pharmaceuticals Earnings Call Transcript: Q2 2026

Aug 3, 2026, 4:30 PM EDT - 15 days ago

Vertex Pharmaceuticals Earnings Call Transcript: Q2 2026

Vertex Pharmaceuticals Earnings release: Q2 2026

Aug 3, 2026, 4:30 PM EDT - 15 days ago

Vertex Pharmaceuticals Earnings release: Q2 2026

Vertex Pharmaceuticals Slides: Q2 2026

Aug 3, 2026, 4:30 PM EDT - 15 days ago

Vertex Pharmaceuticals Slides: Q2 2026

Vertex Pharmaceuticals Quarterly report: Q2 2026

Aug 3, 2026, 4:30 PM EDT - 15 days ago

Vertex Pharmaceuticals Quarterly report: Q2 2026

Vertex Pharmaceuticals reports Q2 adjusted EPS $4.73, consensus $4.75

2026-08-03T20:05:52.000Z - 15 days ago

Vertex Pharmaceuticals reports Q2 adjusted EPS $4.73, consensus $4.75

Vertex Pharmaceuticals ups FY26 revenue view to $13.1B-$13.2B, consensus $13.05B

2026-08-03T20:05:36.000Z - 15 days ago

Vertex Pharmaceuticals ups FY26 revenue view to $13.1B-$13.2B, consensus $13.05B

Vertex raises annual revenue forecast on cystic fibrosis drugs strength

Aug 3, 2026, 4:04 PM EDT - 15 days ago

Vertex raises annual revenue forecast on cystic fibrosis drugs strength

Vertex Reports Second Quarter 2026 Financial Results

Aug 3, 2026, 4:01 PM EDT - 15 days ago

Vertex Reports Second Quarter 2026 Financial Results

AbCellera announces collaboration with Vertex Pharmaceuticals

2026-07-29T11:27:06.000Z - 21 days ago

AbCellera announces collaboration with Vertex Pharmaceuticals

ABCL

Vertex Pharmaceuticals price target raised to $585 from $545 at UBS

2026-07-13T16:35:19.000Z - 5 weeks ago

Vertex Pharmaceuticals price target raised to $585 from $545 at UBS

Vertex Pharmaceuticals price target raised to $560 from $542 at Truist

2026-07-13T13:55:19.000Z - 5 weeks ago

Vertex Pharmaceuticals price target raised to $560 from $542 at Truist

How to Ride the $2.6 Trillion Merger Boom With High-Growth Stocks

Jul 8, 2026, 3:00 AM EDT - 6 weeks ago

How to Ride the $2.6 Trillion Merger Boom With High-Growth Stocks

CRNX

Vertex to Announce Second Quarter 2026 Financial Results on August 3rd

Jul 7, 2026, 4:00 PM EDT - 6 weeks ago

Vertex to Announce Second Quarter 2026 Financial Results on August 3rd

Crinetics shares surge after Vertex agrees to $10B cash buyout

Jul 7, 2026, 9:38 AM EDT - 6 weeks ago

Crinetics shares surge after Vertex agrees to $10B cash buyout

CRNX

SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Crinetics Pharmaceuticals, Inc. (CRNX)

Jul 7, 2026, 9:28 AM EDT - 6 weeks ago

SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Crinetics Pharmaceuticals, Inc. (CRNX)

CRNX

This Biotech Stock Is Soaring 99% After Vertex Agrees to Takeover Deal

Jul 7, 2026, 7:33 AM EDT - 6 weeks ago

This Biotech Stock Is Soaring 99% After Vertex Agrees to Takeover Deal

CRNX

Vertex Pharmaceuticals to Acquire Crinetics Pharmaceuticals for $10 Billion

Jul 6, 2026, 5:02 PM EDT - 6 weeks ago

Vertex Pharmaceuticals to Acquire Crinetics Pharmaceuticals for $10 Billion

CRNX

Vertex Pharmaceuticals Transcript: M&A announcement

Jul 6, 2026, 4:30 PM EDT - 6 weeks ago

Vertex Pharmaceuticals Transcript: M&A announcement

Vertex Pharmaceuticals Press release: M&A announcement

Jul 6, 2026, 4:30 PM EDT - 6 weeks ago

Vertex Pharmaceuticals Press release: M&A announcement

Vertex Pharmaceuticals Slides: M&A announcement

Jul 6, 2026, 4:30 PM EDT - 6 weeks ago

Vertex Pharmaceuticals Slides: M&A announcement

Vertex to buy Crinetics in $10 billion deal

Jul 6, 2026, 4:10 PM EDT - 6 weeks ago

Vertex to buy Crinetics in $10 billion deal

CRNX

Vertex to Acquire Crinetics Pharmaceuticals

Jul 6, 2026, 4:04 PM EDT - 6 weeks ago

Vertex to Acquire Crinetics Pharmaceuticals

CRNX

Vertex Announces US FDA Approval for Expanded Use of CASGEVY® for the Treatment of People Ages 2 Years and Older With Sickle Cell Disease or Transfusion-Dependent Beta Thalassemia

Jul 1, 2026, 7:58 PM EDT - 6 weeks ago

Vertex Announces US FDA Approval for Expanded Use of CASGEVY® for the Treatment of People Ages 2 Years and Older With Sickle Cell Disease or Transfusion-Dependent Beta Thalassemia

US FDA approves Vertex's gene therapy for sickle cell disease in children as young as two

Jul 1, 2026, 6:45 PM EDT - 6 weeks ago

US FDA approves Vertex's gene therapy for sickle cell disease in children as young as two

3 Companies Redefining Healthcare Innovation

Jun 24, 2026, 7:41 AM EDT - 2 months ago

3 Companies Redefining Healthcare Innovation

CMPS CRSP

Vertex Presents New Data on CASGEVY®, Including First European Presentation of Data in Children Ages 5–11, at the European Hematology Association Congress and Announces Additional Global Regulatory Submissions

Jun 11, 2026, 2:01 AM EDT - 2 months ago

Vertex Presents New Data on CASGEVY®, Including First European Presentation of Data in Children Ages 5–11, at the European Hematology Association Congress and Announces Additional Global Regulatory Submissions

Vertex Pharmaceuticals Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 10, 2026, 11:20 AM EDT - 2 months ago

Vertex Pharmaceuticals Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Vertex Presents New Data on ALYFTREK® at European Cystic Fibrosis Conference

Jun 5, 2026, 12:00 PM EDT - 2 months ago

Vertex Presents New Data on ALYFTREK® at European Cystic Fibrosis Conference

Vertex to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference on June 10

Jun 3, 2026, 4:00 PM EDT - 2 months ago

Vertex to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference on June 10

Vertex Announces US FDA Acceptance of Biologics License Application for Accelerated Approval of Povetacicept in IgA Nephropathy

Jun 1, 2026, 8:00 AM EDT - 2 months ago

Vertex Announces US FDA Acceptance of Biologics License Application for Accelerated Approval of Povetacicept in IgA Nephropathy

Vertex Pharmaceuticals Transcript: Bernstein 42nd Annual Strategic Decisions Conference

May 29, 2026, 9:00 AM EDT - 2 months ago

Vertex Pharmaceuticals Transcript: Bernstein 42nd Annual Strategic Decisions Conference

Vertex Pharmaceuticals Transcript: RBC Capital Markets Global Healthcare Conference 2026

May 19, 2026, 2:35 PM EDT - 3 months ago

Vertex Pharmaceuticals Transcript: RBC Capital Markets Global Healthcare Conference 2026

Vertex to Participate in Upcoming May Investor Conferences

May 11, 2026, 4:00 PM EDT - 3 months ago

Vertex to Participate in Upcoming May Investor Conferences

Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia in Germany

May 6, 2026, 7:01 AM EDT - 3 months ago

Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia in Germany

Vertex Pharmaceuticals Earnings Call Transcript: Q1 2026

May 4, 2026, 4:30 PM EDT - 3 months ago

Vertex Pharmaceuticals Earnings Call Transcript: Q1 2026

Vertex Pharmaceuticals Earnings release: Q1 2026

May 4, 2026, 4:30 PM EDT - 3 months ago

Vertex Pharmaceuticals Earnings release: Q1 2026

Vertex Pharmaceuticals Slides: Q1 2026

May 4, 2026, 4:30 PM EDT - 3 months ago

Vertex Pharmaceuticals Slides: Q1 2026

Vertex Pharmaceuticals Quarterly report: Q1 2026

May 4, 2026, 4:30 PM EDT - 3 months ago

Vertex Pharmaceuticals Quarterly report: Q1 2026

Vertex tops profit estimates as sales of new cystic fibrosis drug surge

May 4, 2026, 4:04 PM EDT - 3 months ago

Vertex tops profit estimates as sales of new cystic fibrosis drug surge

Vertex Reports First Quarter 2026 Financial Results

May 4, 2026, 4:01 PM EDT - 3 months ago

Vertex Reports First Quarter 2026 Financial Results

Vertex Pharmaceuticals Proxy statement: Proxy filing

Apr 29, 2026, 8:00 AM EDT - 4 months ago

Vertex Pharmaceuticals Proxy statement: Proxy filing

Vertex to Announce First Quarter 2026 Financial Results on May 4th

Apr 6, 2026, 4:00 PM EDT - 4 months ago

Vertex to Announce First Quarter 2026 Financial Results on May 4th

Vertex Pharmaceuticals Proxy statement: Proxy filing

Apr 2, 2026, 8:00 AM EDT - 4 months ago

Vertex Pharmaceuticals Proxy statement: Proxy filing

Vertex Pharmaceuticals Proxy statement: Proxy filing

Apr 2, 2026, 8:00 AM EDT - 4 months ago

Vertex Pharmaceuticals Proxy statement: Proxy filing

Vertex Announces US FDA Approval for Label Extensions of ALYFTREK® and TRIKAFTA®, Expanding Availability of These Medicines to ~95% of All People With CF in the United States

Apr 1, 2026, 7:30 AM EDT - 5 months ago

Vertex Announces US FDA Approval for Label Extensions of ALYFTREK® and TRIKAFTA®, Expanding Availability of These Medicines to ~95% of All People With CF in the United States

TrumpRx lists many medicines at prices higher than paid in UK

Mar 18, 2026, 2:23 PM EDT - 5 months ago

TrumpRx lists many medicines at prices higher than paid in UK

ABBV AMGN AZN BMY GILD GSK JNJ

Vertex Pharmaceuticals Transcript: Barclays 28th Annual Global Healthcare Conference

Mar 11, 2026, 11:30 AM EDT - 5 months ago

Vertex Pharmaceuticals Transcript: Barclays 28th Annual Global Healthcare Conference

This Pharmaceutical Stock Is Leading the S&P 500 Higher Tuesday, After 'Remarkable' Trial Results

Mar 10, 2026, 1:22 PM EDT - 5 months ago

This Pharmaceutical Stock Is Leading the S&P 500 Higher Tuesday, After 'Remarkable' Trial Results

Vertex passes key test In quest to treat kidney diseases

Mar 10, 2026, 10:54 AM EDT - 5 months ago

Vertex passes key test In quest to treat kidney diseases

Vertex Pharmaceuticals Transcript: Leerink Global Healthcare Conference 2026

Mar 10, 2026, 10:00 AM EDT - 5 months ago

Vertex Pharmaceuticals Transcript: Leerink Global Healthcare Conference 2026

Vertex's kidney disease drug meets main goal in late-stage trial

Mar 9, 2026, 4:13 PM EDT - 5 months ago

Vertex's kidney disease drug meets main goal in late-stage trial

Vertex Announces Positive Week 36 Interim Analysis Results for Primary and All Secondary Endpoints in the RAINIER Phase 3 Trial of Povetacicept in Adults With IgA Nephropathy

Mar 9, 2026, 4:02 PM EDT - 5 months ago

Vertex Announces Positive Week 36 Interim Analysis Results for Primary and All Secondary Endpoints in the RAINIER Phase 3 Trial of Povetacicept in Adults With IgA Nephropathy

Vertex to Participate in Upcoming March Investor Conferences

Mar 5, 2026, 4:00 PM EST - 5 months ago

Vertex to Participate in Upcoming March Investor Conferences

Vertex to Present New Data on JOURNAVX® That Demonstrates Effective Pain Management Following Aesthetic and Reconstructive Procedures

Mar 5, 2026, 10:00 AM EST - 5 months ago

Vertex to Present New Data on JOURNAVX® That Demonstrates Effective Pain Management Following Aesthetic and Reconstructive Procedures

Vertex Pharmaceuticals Transcript: TD Cowen 46th Annual Health Care Conference

Mar 3, 2026, 9:10 AM EST - 6 months ago

Vertex Pharmaceuticals Transcript: TD Cowen 46th Annual Health Care Conference

Vertex to Participate in TD Cowen 46th Annual Health Care Conference on March 3

Feb 17, 2026, 4:00 PM EST - 6 months ago

Vertex to Participate in TD Cowen 46th Annual Health Care Conference on March 3

Vertex Pharmaceuticals Earnings Call Transcript: Q4 2025

Feb 12, 2026, 4:30 PM EST - 6 months ago

Vertex Pharmaceuticals Earnings Call Transcript: Q4 2025

Vertex Pharmaceuticals Annual report: Q4 2025

Feb 12, 2026, 4:30 PM EST - 6 months ago

Vertex Pharmaceuticals Annual report: Q4 2025

Vertex Pharmaceuticals Earnings release: Q4 2025

Feb 12, 2026, 4:30 PM EST - 6 months ago

Vertex Pharmaceuticals Earnings release: Q4 2025

Vertex Pharmaceuticals Slides: Q4 2025

Feb 12, 2026, 4:30 PM EST - 6 months ago

Vertex Pharmaceuticals Slides: Q4 2025

Vertex Pharma forecasts 2026 revenue in-line, expects growth in cystic fibrosis treatments

Feb 12, 2026, 4:06 PM EST - 6 months ago

Vertex Pharma forecasts 2026 revenue in-line, expects growth in cystic fibrosis treatments

Vertex Reports Fourth Quarter and Full Year 2025 Financial Results

Feb 12, 2026, 4:01 PM EST - 6 months ago

Vertex Reports Fourth Quarter and Full Year 2025 Financial Results

WuXi Biologics and Vertex Sign License and Research Service Agreement for T-cell Engager

Feb 2, 2026, 10:08 PM EST - 7 months ago

WuXi Biologics and Vertex Sign License and Research Service Agreement for T-cell Engager

Final Trades: Vertex Pharma, Kimberly-Clark, S&P Global and Exxon Mobil

Jan 22, 2026, 1:19 PM EST - 7 months ago

Final Trades: Vertex Pharma, Kimberly-Clark, S&P Global and Exxon Mobil

KMB XOM SPGI

Vertex to Announce Fourth Quarter and Full Year 2025 Financial Results on February 12th

Jan 20, 2026, 4:00 PM EST - 7 months ago

Vertex to Announce Fourth Quarter and Full Year 2025 Financial Results on February 12th

Vertex Pharmaceuticals Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 5:15 PM EST - 7 months ago

Vertex Pharmaceuticals Transcript: 44th Annual J.P. Morgan Healthcare Conference

Vertex Pharmaceuticals Slides: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 5:15 PM EST - 7 months ago

Vertex Pharmaceuticals Slides: 44th Annual J.P. Morgan Healthcare Conference

Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings

Jan 11, 2026, 5:00 PM EST - 7 months ago

Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings

Vertex to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 12

Dec 22, 2025, 4:00 PM EST - 8 months ago

Vertex to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 12

Vertex's gene therapy shows promise in younger children with blood disorders

Dec 6, 2025, 7:04 AM EST - 9 months ago

Vertex's gene therapy shows promise in younger children with blood disorders

Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions

Dec 6, 2025, 7:01 AM EST - 9 months ago

Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions

Vertex Pharmaceuticals Transcript: Citi Annual Global Healthcare Conference 2025

Dec 3, 2025, 9:00 AM EST - 9 months ago

Vertex Pharmaceuticals Transcript: Citi Annual Global Healthcare Conference 2025

Vertex to Participate in the Citi's 2025 Global Healthcare Conference on December 3

Nov 19, 2025, 4:00 PM EST - 9 months ago

Vertex to Participate in the Citi's 2025 Global Healthcare Conference on December 3

Vertex Pharmaceuticals Transcript: UBS Global Healthcare Conference 2025

Nov 11, 2025, 10:15 AM EST - 10 months ago

Vertex Pharmaceuticals Transcript: UBS Global Healthcare Conference 2025

Vertex Pharmaceuticals Transcript: Study Update

Nov 8, 2025, 8:00 PM EST - 10 months ago

Vertex Pharmaceuticals Transcript: Study Update

Vertex Pharmaceuticals Slides: Study Update

Nov 8, 2025, 8:00 PM EST - 10 months ago

Vertex Pharmaceuticals Slides: Study Update

Vertex Presents Updated Phase 1/2 Data From RUBY-3 Study That Continue to Demonstrate Best-in-Class Potential for Povetacicept in Adults with IgA Nephropathy and Primary Membranous Nephropathy at American Society of Nephrology Kidney Week

Nov 8, 2025, 5:15 PM EST - 10 months ago

Vertex Presents Updated Phase 1/2 Data From RUBY-3 Study That Continue to Demonstrate Best-in-Class Potential for Povetacicept in Adults with IgA Nephropathy and Primary Membranous Nephropathy at American Society of Nephrology Kidney Week

Committee stocks on the move: Uber and Vertex Pharma

Nov 4, 2025, 1:22 PM EST - 10 months ago

Committee stocks on the move: Uber and Vertex Pharma

UBER

Vertex Pharmaceuticals Earnings Call Transcript: Q3 2025

Nov 3, 2025, 4:30 PM EST - 10 months ago

Vertex Pharmaceuticals Earnings Call Transcript: Q3 2025

Vertex Pharmaceuticals Quarterly report: Q3 2025

Nov 3, 2025, 4:30 PM EST - 10 months ago

Vertex Pharmaceuticals Quarterly report: Q3 2025

Vertex Pharmaceuticals Earnings release: Q3 2025

Nov 3, 2025, 4:30 PM EST - 10 months ago

Vertex Pharmaceuticals Earnings release: Q3 2025

Vertex Pharmaceuticals Slides: Q3 2025

Nov 3, 2025, 4:30 PM EST - 10 months ago

Vertex Pharmaceuticals Slides: Q3 2025

Vertex beats quarterly estimates on cystic fibrosis demand, new drugs

Nov 3, 2025, 4:20 PM EST - 10 months ago

Vertex beats quarterly estimates on cystic fibrosis demand, new drugs

Vertex Reports Third Quarter 2025 Financial Results

Nov 3, 2025, 4:02 PM EST - 10 months ago

Vertex Reports Third Quarter 2025 Financial Results

Vertex to Participate in the UBS Global Healthcare Conference on November 11

Oct 27, 2025, 4:00 PM EDT - 10 months ago

Vertex to Participate in the UBS Global Healthcare Conference on November 11

Vertex Presents New Data Across Portfolio of Cystic Fibrosis Medicines Including ALYFTREK® at the North American Cystic Fibrosis Conference

Oct 23, 2025, 9:00 AM EDT - 10 months ago

Vertex Presents New Data Across Portfolio of Cystic Fibrosis Medicines Including ALYFTREK® at the North American Cystic Fibrosis Conference

NightBreeze
NightBreeze Aug. 19 at 1:00 PM
$VRTX Played possum now raging. I see you.
0 · Reply
Jblack500
Jblack500 Aug. 18 at 5:15 PM
$VRTX $ELAN $MRK $GILD $HALO ARWR BMY current basket...vrtx recent new position...added to ELAN today. Sell-off after er created opportunity. Multiple insiders made open market buys on 8/7 near this level.
0 · Reply
svertical1
svertical1 Aug. 18 at 5:14 PM
$VRTX Pain important but Pove is still the game changer. Still not too late for Vertex to modify strategy of Journavx pricing. Pain is not a rare disease.
0 · Reply
OffHisGame88
OffHisGame88 Aug. 18 at 4:07 PM
$VRTX defensives going to be key in the fall
1 · Reply
DonJulio
DonJulio Aug. 18 at 3:13 PM
$VRTX 🔥
0 · Reply
Merlintrader
Merlintrader Aug. 18 at 12:02 AM
Vertex Pharmaceuticals ($VRTX) Stock Hub 2026: The Cystic Fibrosis Fortress, The Pain Launch, And The $10B Crinetics Acquisition https://www.merlintrader.com/vertex-pharmaceuticals-stock-hub/
0 · Reply
Jblack500
Jblack500 Aug. 17 at 5:14 PM
$VRTX 600 dollar stock
0 · Reply
JFDI
JFDI Aug. 17 at 3:58 PM
$VRTX engulfer off the 10d
1 · Reply
Clairebear1
Clairebear1 Aug. 15 at 4:09 PM
$VRTX What’s the reason for Vertex delay in advancing Nav1.7 and next gen Nav1.8 sodium channel blockers to treat pain?. It’s been years in preclinical stage and competitors to Journavx are progressing in clinical trials. I hope Vertex success in serial innovation in CF can be replicated in pain. Otherwise perhaps they need to do another acquisition of someone who’s actually managed to achieve something superior to Journavx before it’s made obsolete like what happened to Vertex in hepatitis C with telaprevir after Gilead acquired Pharmasset in 2011.
1 · Reply
StUngarjr
StUngarjr Aug. 15 at 3:12 PM
$VRTX this stock spits a bit here every time hopefully not this time, but I got my finger on the trigger
0 · Reply
BuffettStyleInvestments
BuffettStyleInvestments Aug. 15 at 8:40 AM
$PTLO $TRLV $NN $VRTX Portillo's benefits from restaurant traffic and expansion, TRLV remains speculative, NN remains execution-dependent, and Vertex benefits from pharmaceutical demand and pipeline expansion. I'm watching same-store sales, funding, execution, and prescription growth.
0 · Reply
akinyo
akinyo Aug. 14 at 7:49 PM
$VRTX Doesn’t seem to be able to hold over $500.
0 · Reply
HawkEye828
HawkEye828 Aug. 14 at 6:59 PM
$PROK No reason for this to be down...great opportunity to load. This will be a multibagger. No brainer. On target for kidney drug that will save the government in Billions in dialysis. 70 % positive response rate. ProKidney (NASDAQ: PROK) is a clinical-stage biotechnology company founded in 2015 and headquartered in Winston-Salem, North Carolina. It is focused on developing a first-of-its-kind autologous cell therapy named rilparencel (REACT®) designed to preserve kidney function and delay or prevent the need for dialysis in patients with advanced chronic kidney disease (CKD) $LLY ,$AMGN, $VRTX, $GILD
0 · Reply
DeadInvestor
DeadInvestor Aug. 14 at 6:52 PM
$TVTX New 13G’s filed. Two are clearly passive investments. One is unidentified. Could be a potential acquirer like $NVS or $VRTX. Date Type Filer Stake Aug 6 13G/A Vanguard (unconfirmed for this specific date) Historically ~7%+ Aug 7 13G (new) Unidentified Unknown Aug 12 13G (new) Bank of America Corp. 5.8% (5,439,155 shares)
0 · Reply
SapphireInvestments
SapphireInvestments Aug. 14 at 3:15 PM
$BAC $ONDS $VRTX $CMG Bank of America benefits from banking activity and capital markets, Ondas advances autonomous drone and private-wireless technologies, Vertex benefits from pharmaceutical demand and pipeline expansion, and Chipotle benefits from restaurant traffic and pricing. I'm watching credit quality, contract wins, clinical catalysts, and same-store sales.
1 · Reply
NightBreeze
NightBreeze Aug. 14 at 2:52 PM
$VRTX Giving up all that gain from SION debacle. Maddening. Wish I had more dry powder to add
0 · Reply
pflory23
pflory23 Aug. 14 at 2:11 PM
$VRTX frustrating…. Didn’t cut on the push. Waiting for the move to $600
0 · Reply
Jblack500
Jblack500 Aug. 14 at 2:05 PM
$VRTX added in 503's..will add down to about 490. Should move to 600's
0 · Reply
JimmyOcarri
JimmyOcarri Aug. 13 at 9:20 PM
$VRTX nice d
0 · Reply
akinyo
akinyo Aug. 13 at 8:05 PM
$VRTX back to sub 500?
0 · Reply
Fred_Sigma_Invest
Fred_Sigma_Invest Aug. 12 at 2:37 PM
$PEPG $VRTX $SRPT $DYN $RNA
0 · Reply
DayTradingNurse
DayTradingNurse Aug. 12 at 12:19 PM
$SION Waiting on the floor to set before I enter. The floor is likely set, but I would give it another two weeks or so before jumping in. The closest related stock to what they are trying to do $VRTX trades over $500 a share. Currently in $MWC where the free float is about 7 million and trading at about $1.50. Floor has been set for two weeks and closest related stocks trade in the 8 to 9 dollar range.
0 · Reply